December 3, 2025 07:20 AM EST
Updated 02:27 PM
R&D
Updated: Pharvaris’ hereditary angioedema drug gets Phase 3 win
Elizabeth Cairns
Senior biopharma journalist
Pharvaris’ on-demand oral treatment for hereditary angioedema (HAE) attacks alleviated symptoms significantly faster than placebo, according to topline data from a Phase 3 trial …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS
Analyst – Life Sciences Strategy & Intelligence
Sedulo Group
Remote
VIEW JOB OFFER
post your job now